TP53 and neoplasm: The earlier investigation of 15 molecularly analysed BRAFV600E CRC tumour samples of patients treated with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib harboured alterations in the WNT and p53 pathways without a clear correlation with treatment outcome.